相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Joerg Herrmann et al.
EUROPEAN HEART JOURNAL (2022)
Cardiotoxic effects of angiogenesis inhibitors
Stephen J. H. Dobbin et al.
CLINICAL SCIENCE (2021)
MEK inhibitors for the treatment of non-small cell lung cancer
Jing Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
Daan C. H. van Dorst et al.
CIRCULATION RESEARCH (2021)
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries
Avirup Guha et al.
CANCER MEDICINE (2021)
Recent Advances in the Treatment of Melanoma
Brendan D. Curti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies
Janice M. Bonsu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis
Charles Dolladille et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2020)
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from theCardio-OncologyStudyGroup of theHeartFailureAssociation of theEuropeanSociety ofCardiology in collaboration with theInternationalCardio-OncologySociety
Alexander R. Lyon et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis
Mathilde Berger et al.
CANCER MEDICINE (2020)
Systemic Therapy for Melanoma: ASCO Guideline
Rahul Seth et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Current State of Target Treatment in BRAF Mutated Melanoma
Enrica Teresa Tanda et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials
Janice Bonsu et al.
CIRCULATION (2019)
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto et al.
NATURE MEDICINE (2019)
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J. Gogas et al.
EUROPEAN JOURNAL OF CANCER (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
O. Michielin et al.
ANNALS OF ONCOLOGY (2019)
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Lucie Heinzerling et al.
ESMO OPEN (2019)
Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors A Systematic Review and Meta-analysis
Raluca I. Mincu et al.
JAMA NETWORK OPEN (2019)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors
Enrico Bronte et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors
Stephen J. H. Dobbin et al.
HEART (2018)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
Jose Luis Zamorano et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
Adil Daud et al.
ONCOLOGIST (2017)
Increased Apoptosis in the Paraventricular Nucleus Mediated by AT1R/Ras/ERK1/2 Signaling Results in Sympathetic Hyperactivity and Renovascular Hypertension in Rats after Kidney Injury
Hongguo Zhu et al.
FRONTIERS IN PHYSIOLOGY (2017)
Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism
Mary Banks et al.
CARDIOVASCULAR TOXICOLOGY (2017)
Cancer Treatment-Induced Arrhythmias Focus on Chemotherapy and Targeted Therapies
Vitaly Buza et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
The MEK1 inhibitors UO126 and PD98059 block PDGF-AB induced phosphorylation of threonine 292 in porcine smooth muscle cells
Thomas Kubin et al.
CYTOKINE (2017)
Shared Risk Factors in Cardiovascular Disease and Cancer
Ryan J. Koene et al.
CIRCULATION (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
Zachary A. Cooper et al.
ONCOIMMUNOLOGY (2016)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study
Manuela Quaresma et al.
LANCET (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment
Enrico Bronte et al.
ONCOTARGET (2015)
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Sarah J. Welsh et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Ping-Chih Ho et al.
CANCER RESEARCH (2014)
B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophy
Nadine Kramann et al.
CARDIOVASCULAR RESEARCH (2014)
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
James Larkin et al.
LANCET ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.
James A. McCubrey et al.
ONCOTARGET (2012)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell et al.
ONCOTARGET (2011)
Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale
Beth A. Rose et al.
PHYSIOLOGICAL REVIEWS (2010)
IL-10 attenuates TNF-α-induced NFκB pathway activation and cardiomyocyte apoptosis
Sanjiv Dhingra et al.
CARDIOVASCULAR RESEARCH (2009)
The RAS/MAPK syndromes: Novel roles of the RAS pathway in human genetic disorders
Yoko Aoki et al.
HUMAN MUTATION (2008)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism
Kazuyuki Naitoh et al.
CARDIOVASCULAR RESEARCH (2006)
MEK hyperphosphorylation coincides with cell cycle shut down of cultured smooth muscle cells
S Vogel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo
DJ Lips et al.
CIRCULATION (2004)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload
IS Harris et al.
CIRCULATION (2004)
An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development
MK Saba-El-Leil et al.
EMBO REPORTS (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells
Y Iijima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor
I Zachary
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2001)
分享论文
